Relapse after non‐metastatic rhabdomyosarcoma: The impact of routine surveillance imaging on early detection and post‐relapse survival-Reference-Cited by-同舟云学术

Relapse after non‐metastatic rhabdomyosarcoma: The impact of routine surveillance imaging on early detection and post‐relapse survival

Published:2022-11-21 Issue:2 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Casanova Michela¹,Bergamaschi Luca¹^ORCID,Chiaravalli Stefano¹,Morosi Carlo²,Livellara Virginia¹,Hovsepyan Shushan¹,Sironi Giovanna¹,Puma Nadia¹,Nigro Olga¹^ORCID,Gattuso Giovanna¹^ORCID,Luksch Roberto¹^ORCID,Terenziani Monica¹^ORCID,Spreafico Filippo¹^ORCID,Meazza Cristina¹^ORCID,Podda Marta¹,Biassoni Veronica¹,Schiavello Elisabetta¹^ORCID,Gasparini Patrizia³^ORCID,Vennarini Sabina⁴,Massimino Maura¹^ORCID,Ferrari Andrea¹^ORCID

Affiliation:

1. Pediatric Oncology Unit Medical Oncology and Hematology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

2. Radiology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

3. Tumor Genomics Unit Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

4. Pediatric Radiotherapy Unit Fondazione IRCCS Istituto Nazionale Tumori Milan Italy

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30095

Reference44 articles.

1. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

2. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

3. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

4. Relapsed Rhabdomyosarcoma